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Abstract
Purpose Therapeutic strategies for prostate cancer (PCa) have been evolving dramatically worldwide. The current article 
reports on the evolution of surgical management strategies for PCa in Italy.
Methods The data from two independent Italian multicenter projects, the MIRROR-SIU/LUNA (started in 2007, holding 
data of 890 patients) and the Pros-IT-CNR project (started in 2014, with data of 692 patients), were compared. Differences 
in patients’ characteristics were evaluated. Multivariable logistic regression models were used to identify characteristics 
associated with robot-assisted (RA) procedure, nerve sparing (NS) approach, and lymph node dissection (LND).
Results The two cohorts did not differ in terms of age and prostate-specific antigen (PSA) levels at biopsy. Patients enrolled 
in the Pros-IT-CNR project more frequently were submitted to RA (58.8% vs 27.6%, p < 0.001) and NS prostatectomy (58.4% 
vs. 52.9%, p = 0.04), but received LND less frequently (47.7% vs. 76.7%, p < 0.001), as compared to the MIRROR-SIU/
LUNA patients.
At multivariate logistic models, Lower Gleason Scores (GS) and PSA levels were significantly associated with RA prosta-
tectomy in both cohorts. As for the MIRROR-SIU/LUNA data, clinical T-stage was a predictor for NS (OR = 0.07 for T3, 
T4) and LND (OR = 2.41 for T2) procedures. As for Pros-IT CNR data, GS ≥ (4 + 3) and positive cancer cores ≥ 50% were 
decisive factors both for NS (OR 0.29 and 0.30) and LND (OR 7.53 and 2.31) strategies.
Conclusions PCa management has changed over the last decade in Italian centers: RA and NS procedures without LND have 
become the methods of choice to treat newly medium–high risk diagnosed PCa.
Keywords Prostate cancer · Pros-IT CNR study · MIRROR SIU/LUNA study · Robotic procedures · Nerve sparing · 
Lymph node dissection
Introduction
Treatment pathways for prostate cancer (PCa) patients have 
been evolving dramatically over recent years worldwide, 
leading to different patterns of surgical strategies through-
out the development and improvement of diagnostic and 
staging tools, such as preoperative nomograms, multidis-
ciplinary guidelines, and the advent of robotic technology. 
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IT CNR Study Group are listed in Acknowledgements section.
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Intensifying prostate-specific antigen (PSA) screening 
efforts, lowering PSA threshold for prostate biopsy and the 
ever-growing number of samples taken have contributed to 
the rising incidence rates of PCa [1].
Despite these changes, radical prostatectomy (RP) 
remains the surgical standard treatment for patients with 
organ confined PCa [2, 3]. Moreover, throughout time, 
available evidence focused on general topics regarding 
RP, including the role of robot assisted (RA) procedures, 
nerve sparing (NS) approach and/or lymph node dissection 
(LND). Likewise, Internet has become an important source 
of information for patients on waiting lists for RP, but only 
36% of the information provided about PCa treatment is in 
accordance with the guidelines of the European Association 
of Urology (EAU) [4]. In addition, there seems to be a low 
compliance with guidelines by Italian urologists [5].
In 2007, the Italian Urological Association (SIU) with 
the Leading Urological No-profit Foundation for advanced 
Research (LUNA—Fondazione SIU Onlus) instituted the 
Multicenter Italian Report on Radical prostatectomy Out-
come and Research (MIRROR), involving 136 Urology 
Departments located throughout the country [6]. In 2014, 
the PROState cancer monitoring in Italy, from the National 
Research Council (Pros-IT CNR) study, prospective, mul-
ticenter project monitoring PCa patients attending 97 Urol-
ogy, Radiation therapy, and Oncology Departments located 
throughout Italy, was instituted [7].
The aim of this retrospective observational study was 
to analyze and compare data from the two PCa patients’ 
cohorts, mostly in terms of RA, NS, and LND rates observed 
over the 7-year time frame.
Materials and methods
The MIRROR, an independent prospective observational 
study started in Italy in 2007, aimed to create a register of 
patient surgically treated for PCa [6]. Overall, consecutive 
patients, from 2007 to 2011, underwent RP in 136 participat-
ing centers. The following information was gathered from 
all participating patients: age, calculated body mass index 
(BMI), preoperative tumor characteristics (i.e., serum PSA 
value, clinical T-stage, and GS at biopsy, number and per-
cent of positive cancer cores). Likewise, patients’ preop-
erative general quality of life (QoL) was evaluated using 
the validated translation of the Short Form Health Survey 
(SF-12) [8]; their PCa-specific QoL was evaluated using 
the validated translation of the University of California Los 
Angeles-Prostate Cancer Index (UCLA-PCI) [9]. The surgi-
cal data (RA vs. non-RA RP; NS vs. non-NS; LND vs. no 
LND) have also been collected.
The Pros-IT CNR is an ongoing, prospective, multicenter 
study, aimed at monitoring the QoL of a sample of Italian 
treatment-naïve males diagnosed with biopsy-verified PCa 
after September 1th 2014. Overall, patients who met study’s 
eligibility criteria were enrolled in the 97 participating cent-
ers (51 Urology, 39 Radiation Oncology, 7 Medical Oncol-
ogy) [7]. Baseline questionnaire was administered at the time 
of PCa diagnosis, and follow-up evaluations were planned 
for a 60-months period [10, 11]. The data on patients’ demo-
graphics, BMI, comorbidities, initial diagnosis, and cancer 
staging (i.e., PSA levels, clinical T-stage, biopsy GS, details 
regarding the prostate biopsy) were collected. Patients’ gen-
eral and PCa-specific QoL at diagnosis were evaluated using 
the SF-12 and UCLA-PCI questionnaires. Only data from 
patients who underwent RP and whose QoL records were 
complete entered this analysis. The surgical data (robot-
assisted vs. non-robot assisted RP; NS vs. non-NS; LND vs. 
no LND) have also been collected and eventually analyzed.
Both projects, in accordance with the principles of the 
Declaration of Helsinki, were approved by the Ethic Com-
mittee of both coordinating centers and of each participating 
center. All participants provided their informed consent.
RA RP was performed using either the Si or Xi da Vinci 
robotic platform in a four-arm configuration, according to 
centers availability. Trendelenburg tilt was set at 30° in all 
cases. All procedures were performed according to general 
principles and surgical details, previously described [12].
Both Pros-IT CNR and MIRROR data were analyzed 
without imputation of missing data. The normality of dis-
tributions was tested using the Shapiro–Wilk test. The data 
are presented as either means and standard deviation (SD) 
of the mean, or medians and interquartile ranges for quan-
titative variables, and as frequencies and percentages for 
categorical variables. The differences in terms of patients’ 
characteristics between the two cohorts were assessed using 
the Chi-square or the Fisher’s exact test and the Wilcoxon 
rank-sum test.
Multivariable logistic regression models were applied 
to identify the characteristics associated with the use of 
(a) RA, (b) NS approach, and (c) LND in both cohorts. 
Each model was adjusted for age at diagnosis (years), BMI 
(obesity vs normal weight, underweight or overweight), T 
staging at diagnosis (T1 vs T2 or T3-T4), GS at diagnosis 
(3 + 3 vs 3 + 4, 4 + 3, 8+), serum PSA at diagnosis (< 10 vs 
10–20 or  > 20 ng/mL), the percentage of positive cores, 
and D’Amico risk classification (low vs intermediate or high 
risk) [13]. The models were also adjusted for general and 
PCa-specific QoL scores at diagnosis, dichotomized with 
respect to the third quartile (Q3) of their distribution. Signif-
icance was set for a p value < 0.05. Analyses were performed 
using SAS 9.4 statistical software.
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Results
Overall, the data of 890 patients (37%) for the MIRROR 
and 692 (40.6%) for the Pros-IT CNR cohort, respectively, 
who underwent RP and whose QoL information were 
recorded, were finally analyzed.
Patients’ age at diagnosis, median PSA level at biopsy, 
mean BMI and waist circumference value were not differ-
ent between the two groups (Table 1). Conversely, Pros-IT 
CNR cohort had a lower clinical T-stage in a greater rate 
of patients compared to MIRROR cohort (cT1 for 54.3% 
vs 45%; p < 0.0001, respectively), but higher biopsy GS 
(GS 8–10 in 14.2% vs 10.1%; p < 0.0001, respectively). 
Similarly, Pros-IT CNR cohort had a higher mean number 
of cores at biopsy (14.3 ± 4.6 vs 12.6 ± 4.1, p < 0.0001, 
respectively, with a median of 12 for each cohort) and 
higher median percentage of positive cores (33 vs 29; 
p = 0.0123, respectively) as compared to MIRROR cohort.
Pros-IT CNR patients showed higher mean scores on 
the physical component summary (PCS) of the SF-12 
and on the urinary function (UF) (p < 0.0001), the bowel 
Table 1  Patient data and disease 
characteristics
BMI body mass index, PSA prostate-specific antigen
a Underweight: < 18.5  kg/m2, normal weight 18.5–24.9  kg/m2; overweight: 25.0–29.9  kg/m2; 
obese: ≥ 30.0 kg/m2
MIRROR (n = 890) Pros-IT CNR (n = 692) p
Patient’s characteristics
 Age (years) (mean ± SD) 64.9 ± 6.5 64.6 ± 6.7 0.3316
 BMI (kg/m2)
   Mean ± SD 26.4 ± 3.2 26.5 ± 3.2 0.4869
   Underweighta (n, %) 0 (0.0) 2 (0.3) 0.3966
   Normal  weighta (n, %) 252 (35.1) 226 (32.9)
   Overweighta (n, %) 383 (53.3) 368 (53.6)
   Obesea (n, %) 83 (11.6) 90 (13.1)
 Waist circumference (cm) (mean ± SD) 94.3 ± 14.9 93.0 ± 12.1 0.2358
Preoperative tumor features
 Clinical stage (n, %) < 0.0001
   cT1 385 (45.0) 371 (54.3)
   cT2 418 (48.8) 259 (37.9)
   cT3, cT4 45 (5.3) 35 (5.1)
 PSA at biopsy (ng/mL)
   Median, IQR 7.0 (5.1–9.9) 6.9 (5.2–9.9) 0.9375
   < 10, n (%) 669 (75.2) 522 (76.3) 0.6176
   10–20, n (%) 158 (17.8) 122 (17.8)
   > 20, n (%) 63 (7.1) 40 (5.9)
 Gleason Grade Groups at biopsy (n, %)  < 0.0001
   1 554 (62.7) 334 (48.7)
   2 163 (18.5) 160 (23.3)
   3 77 (8.6) 95 (13.8)
   4 66 (7.5) 67 (9.8)
   5 23 (2.6) 30 (4.4)
 D’Amico risk class (n, %) 0.1580
   Low 276 (33.3) 209 (34.0)
   Intermediate 374 (45.2) 251 (40.8)
   High 178 (21.5) 155 (25.2)
Bioptical features
 Number of biopsy cores (mean ± SD) 12.6 ± 4.1 14.3 ± 4.6  < 0.0001
 Percentage of positive cores 0.0123
   Mean ± SD 34.7 ± 24.9 36.1 ± 23.9
   Median, IQR 29 (17–50) 33 (17–50)
   Min, max 0, 100 0, 100
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function (BF) (p = 0.0002) and the bowel bother (BB) 
components (p = 0.0008) of the UCLA-PCI at diagnosis 
(Table S1). Conversely, the two cohorts did not differ 
as far as the mental component summary (MCS) of the 
SF-12 and the urinary bother (UB), the sexual func-
tion (SF) and the sexual bother (SB) components of the 
UCLA-PCI were concerned.
More robotic procedures were carried out in the Pros-
IT CNR than in the MIRROR cohort (58.8% vs 27.6%; 
p < 0.0001; respectively). Nerve sparing approach was 
more common in the Pros-IT CNR group (57.8% vs 
52.9%, p = 0.0449): bilateral NS prostatectomy was per-
formed in 42.6% and 36.3% of the Pros-IT CNR and MIR-
ROR cohort, respectively. Less patients in the Pros-IT 
CNR were submitted to LND than in the MIRROR group 
(47.7% vs. 76.7%; p < 0.0001, respectively).
At logistic regression models (Table S2), the higher 
was the age at diagnosis, the lower was the probability of 
being submitted to RA and NS strategies in both cohorts. 
Advanced age was associated with higher odds of LND 
procedures only in the MIRROR population. Obesity and 
the D’Amico risk class were not associated with any out-
comes taken into consideration.
Gleason score > 4 + 3 at biopsy showed, at multivari-
able analysis, a value of 0.29 (95% CI 0.13–0.68) for the 
MIRROR and 0.37 (95% CI 0.18–0.78) for the Pros-IT 
CNR cohort, respectively. Moreover, the OR related to 
a serum PSA ≥ 20 ng/mL at diagnosis was 0.20 (95% CI 
0.06–0.69) for the MIRROR and 0.40 (95% CI 0.16–1.03) 
for the Pros-IT CNR cohort, respectively (Table S2). The 
clinical T-stage did not emerge to be relevant in Pros-
IT population as well as the RA strategy was concerned 
(OR = 1.47, 95% CI 0.50–4.31). Conversely, clinical 
T-stage was associated with the decision to perform 
both NS and LND in the MIRROR cohort respect to the 
Pros-IT group (OR = 0.07, 95% CI 0.01–0.58 for T3–T4 
and OR = 2.41, 95% CI 1.36–4.27 for T2) (Table S2). 
Biopsy GS ≥ 4 + 3 and a ≥ 50% percentage of positive 
cores was associated with the decision to perform NS 
(OR = 0.29, 95% CI 0.14–0.62 and OR = 0.37, 95% CI 
0.23–0.59, respectively) as well as LND (OR = 7.53, 95% 
CI 3.40–16.7 and OR = 2.31, 95% CI 1.45–3.69, respec-
tively) in the Pros-IT CNR cohort of patients.
Regarding the QoL, lower score on the physical 
component of the SF-12 scale emerged to be a protec-
tive factor against RA only in the MIRROR population 
(OR = 0.53, 95% CI 0.31–0.92). Scores for the SF and 
SB components of the UCLA-PCI at diagnosis below the 
third quartile were associated with RA RP in the MIR-
ROR cohort (SF OR = 2.17, 95% CI 1.13–4.16) and with 
the LND in the Pros-IT CNR one (SB OR = 2.14, 95% CI 
1.24–3.69).
Discussion
It is well established that PCa should be managed on a 
personalized basis [3] and that the surgical strategy and 
approach should be determined on the basis of the patient’s 
demographic and clinical characteristics. The frequency of 
minimally invasive approaches reflects all the important 
technological advancements that have recently taken place 
in the field of urology [14, 15] and dramatically changed 
the management of PCa patients. In fact, 3D magnifica-
tion, Endowrist technology and the use of RA surgery 
have enabled surgeons to develop improved techniques in 
Urology.
The analysis of our data showed that both cohort of 
patients shared similar characteristics (i.e., age, BMI, 
waist circumference, and median serum PSA value) 
(Table1). Therefore, we sought to investigate whether 
some preoperative variables could have been differently 
associated with the surgical decision over the 7-year time 
frame that separated patients’ enrollment between the two 
studies. In this context, parallel multivariate analyses were 
carried out (Table S2).
A first relevant finding was that the number of RA and 
NS procedures increased (27.6–53.4% and from 52.9 to 
57.8%, in the two cohorts, respectively), whereas the fre-
quency of the LND fell down (76.7% vs. 47.7%, respec-
tively). A further analysis also uncovered that selection 
criteria for robotic surgery were mainly based on tumor-
related (i.e.; GS and PSA) rather than patient-related 
characteristics (i.e.; SF-12 PCS and age). In this context, 
surgeons’ experience, skill, and confidence with the RA 
approach seemed to be important factors when intermedi-
ate and high-risk patients were considered.
Furthermore, the comparison between the two pro-
jects (separated by a 7-year time lag) showed that clinical 
T-stage, once considered a crucial step for choosing both 
RA and NS approaches, is no longer relevant; in contrast 
GS at biopsy, once ignored when the NS and LND strate-
gies were being contemplated, is now one of the main 
determinants.
As for LND procedures, GS at biopsy and the percent-
age of positive cores seemed to be the most important 
factors considered. Of clinical relevance, the most recent 
project (i.e., Pros-IT CNR) depicted that patient’s age was 
no longer a determinant for LND compared to seven years 
before [16, 17].
Our findings are in in agreement with evidence cur-
rently available. Although the decision to perform LND 
was not based on a validated nomogram [18, 19], the sin-
gle elements considered by our multivariable models are 
all included in the most popular nomograms available. 
Indeed, the decision to consider single elements rather 
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than a nomogram seemed particularly appropriate given 
the long study period (7 years), the many changes made 
in those nomograms and the different weight of each fac-
tor [16, 17, 20]. This feeling can be further illustrated by 
referring to the Briganti nomogram which predicts lymph 
node involvement in prostate cancer patients. According to 
that model, if a 5–10 ng/ml PSA range predicts an increase 
of only 10 points, the clinical T-stage and GS at biopsy are 
both considered important elements in predicting lymph 
node involvement.
Our data have confirmed the results of the Martini-Clinic 
database that showed that GS, serum PSA levels, and the 
number of positive biopsy cores were independent predic-
tors for LND in both open and RA RP in high-volume cent-
ers [21]. Moreover, even if PSA has kept its importance in 
terms of surgical decision, the percentage of positive cores 
at biopsy has become even more relevant both for NS and 
LND.
These results could be linked to advancements in the 
technical accuracy of robotic surgery and the more precise 
preoperative imaging assessment tools—including magnetic 
resonance [22], fusion biopsy [23], 3D technology [24], 
etc.—that are increasingly being used to evaluate patients 
with PCa.
It should be noted that the significantly higher mean num-
ber of biopsy cores in Pros-IT CNR population might be 
related to the wide time period of the studies, during which 
methods and number of cores significantly changed.
Despite the significant reduction in palpable tumors (cT2: 
48.8% vs. 37.9%) found by the most recent survey (Pros-IT 
CNR), men at the same age and with the same PSA value 
showed the comparable median number of positive cores at 
biopsy (i.e., 12), although they presented different percent-
ages of positive cores (33% vs. 29%). The changes occurred 
over time in the guidelines about prostate biopsies (namely, 
indications, procedures, and interpretation of results) have 
led to a dramatic increase in high grade PCa in the latter as 
compared to the former cohort of patients (GS ≥ 8: 14.2% 
vs.10.1%, respectively) and a concomitant reduction in the 
number of indolent or low grade PCa (GS = 6: 48.7% vs 
62.7%, respectively).
Of further clinical relevance the finding that the D’Amico 
risk class was not associated with the surgical decisions at 
multivariate analyses in both cohorts. This quite unexpected 
result might be linked to the higher impact of single onco-
logic features (such as grade, stage, and PSA) with respect to 
risk classes referring to a combination of variables [25]. In 
addition, criteria for RA procedures have probably changed 
over the last 10 years. In fact, general and cancer-specific 
QoL analyses have demonstrated that nowadays candidates 
for RA RP seem to be more fit and to have better urinary and 
bowel control. On the contrary, patients with urinary and/or 
bowel dysfunction are being offered other treatment options 
[6, 26–28]. Similarly, it is also possible that patients’ expec-
tations in terms of urinary function after RP are currently 
higher than those reported only 10 years ago [6, 26–28].
Finally, while none of the projects seemed to take obe-
sity into consideration during preoperative assessments, in 
accordance with current literature reports, the Pros-IT study 
found a further reduction in terms of the OR for the obese 
patients to be finally considered for RA, NS prostatectomy 
and LND compared to the MIRROR cohort (1.0 vs. 1.8, 0.6 
vs. 0.8 and 0.7 vs. 2.0, respectively) [29, 30].
The present study is not devoid of limitations. First of 
all, we compared the populations of two different studies 
with dissimilar designs, number of patients per center, pro-
posed objectives and methods. Second, since PCa patients 
in the two groups were treated both at referral as well as at 
minor urologic centers, current findings may not be consid-
ered generalizable. Nevertheless, both used the same tests to 
evaluate patients’ general and PCa-related QoL. Moreover, 
selection criteria for robotic surgery are based on tumor-, 
patient-, center- and surgeon-related factors. Owing to the 
primary aims of the studies, these data are not totally avail-
able, and they are not considered in our analysis. However, 
the selection criteria listed above, are partially related to sur-
geon decision-making and maybe they are not entirely gener-
alizable. Key factor for the specific purpose of the analyses, 
the studies referred to two different time frames, an impor-
tant issue when robotic technology is being discussed. These 
limitations may have affected data’s homogeneity and gen-
eralizability. Finally, the lack of information on long-term 
outcomes can be considered a further methodological bias.
Despite these limitations, the multi-institutional expe-
riences outlined here provide a revealing snapshot of the 
Italian trend to use RA RP in case of organ-confided PCa, 
highlighting patient and tumor related factors that continue 
to be considered relevant when surgical options (RA, NS and 
LND) are contemplated.
Overall, the current findings confirm that PCa manage-
ment has dramatically changed over the past single decade, 
mostly because of newly developed therapeutic technologies 
[31]. Our study presents a picture of surgical treatments of 
PCa in a specific country over a specific timeframe. Future 
studies will be able to: assess the impact of the surgeon’s 
experience and skill; evaluate very long-term functional 
and oncological outcomes after robotic vs. open surgery; 
pinpoint criteria for selecting candidates who most could 
benefit from a minimally invasive approach; and compare 
various therapeutic options for PCa and the differences 
attained in low and high volume centers.
To conclude, major technological advancements have 
been fully incorporated in the practice of Italian urologists, 
aiming at reducing the toxicity of the surgical treatment and 
possibly ameliorating outcomes; hopefully, future break-
throughs in surgical techniques and preoperative assessment 
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tools will lead to even better outcomes for patients under-
went RP.
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